In 2011, Pfizer's patent on its high-earning cholesterol drug, Lipitor will expire.According to The Wall Street Journal, Lipitor accounts for about 25% of the drug giant's sales. In 2008, the sale of the drug reportedly raked in $12.7 billion in revenue.
With the patent protection of Lipitor set to cease in approximately 2 years, Pfizer will soon be vulnerable to other drug manufacturers using their profitable formula to create a comparable cholesterol pharmaceutical. Ergo, Pfizer is attempting to be proactive to protect their future bottom line. Part of their profit-protecting strategy is their current attempt to purchase advil manufacturer, Wyeth.
[CLICK HERE for "Today's Fly Or Die Commerce Report: Pfizer's Possible New Acquisition" (1/24/09).]
No comments:
Post a Comment